Erdafitinib for FGFR-mutated urothelial carcinoma

Erdafitinib for FGFR-mutated urothelial carcinoma

VJOncology

1 year
117 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the first results of the primary analysis of the Phase II BLC2001 study (NCT02365597) of erdafitinib in patients with metastatic or unresectable urothelial carcinoma with FGFR alterations. Notably, immune 'cold' patients were observed to respond well to erdafitinib. Dr Siefker-Radtke highlights interesting future directions for this research. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Up Next Autoplay
The Role of Immunotherapy in Bladder Cancer
The Role of Immunotherapy in Bladder Cancer
Category: Bladder Cancer
3 Views
cancergrace 2 weeks
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Category: Bladder Cancer
12 Views
Cancer-News 2 weeks
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
Category: Bladder Cancer
51 Views
Cancer-News 3 months
EV-103 Phase I Trial Presented at #ESMO19
EV-103 Phase I Trial Presented at #ESMO19
Category: Bladder Cancer
25 Views
Cancer-News 3 months
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Category: Bladder Cancer
50 Views
Cancer-News 4 months
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Category: Bladder Cancer
26 Views
Cancer-News 4 months
Strategies for Treating 2nd Line RCC Patients
Strategies for Treating 2nd Line RCC Patients
Category: Bladder Cancer
54 Views
obr 6 months
Treating Newly Diagnosed RCC Patients
Treating Newly Diagnosed RCC Patients
Category: Bladder Cancer
61 Views
obr 6 months
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Category: Bladder Cancer
115 Views
obr 6 months
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Category: Bladder Cancer
52 Views
obr 6 months